Fixed-Oil Excipient Monographs: Development of USP Fixed-Oil Reference Standards - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fixed-Oil Excipient Monographs: Development of USP Fixed-Oil Reference Standards
This article summarizes the development and modernization of the United States Pharmacopeia-National Formulary (USP-NF) fixed-oil excipient monographs. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 102-108


Table XI: Continued monograph modernization for fixed oils.
Conclusion and future development and modernization As shown in Table XI, excipient monograph modernization is a continuing endeavor that requires a consistent approach within a family of excipients. Such an approach is necessary to streamline analytical testing across multiple monographs as well as to keep the number of specific analytical tests to a minimum. This decreases the analytical burden on industry and allows methods to be referenced in monographs (e.g., from a general chapter).

USP continues to update USP−NF to provide standards for articles, including revised specifications based on advances in analytical and metrological science. USP ECs also rely on stakeholders’ and sponsors’ comments to keep monographs current. Emerging methodologies such as carbon number testing, C13/C12/ratio testing, and chemometrics can be considered as they become commonly adopted by stakeholders.

Acknowledgments

The authors would like to thank USP visiting scientists Hua Yin, MS (Chinese Pharmacopoeia) and Cheetham Mingle, MS (Food and Drug Board, Ghana) for their contributions to the monograph modernization projects for almond oil and castor oil, respectively. USP laboratory staff (Samir Z. Wahab; Patricia White (retired); Shane X. Tan; MinLi Liu; Johanna M. Smeller; Zarema K. Kassymberk; Eduardo R. Lim; Kornepati V. Ramakrishna; David C. Parmelee; Karen V. Gilbert; and Nadejda V. Soukhova) are acknowledged for their support in updating the documentary standards. The authors thank Stefan Schuber, PhD, MS, ELS, of USP for editorial assistance.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here